Please assess the completion status of the following clinical trial:

Trial Title: PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ages \>= 50 and \<= 85 years~* Informed consent form (ICF) signed by the subject or legally acceptable representative.~* Clinical diagnosis of dementia due to possible or probable Alzheimer's disease~* Mini-Mental State Examination score \>= 16 and \<= 26 at screening~* If female, postmenopausal for at least 1 year~* Patient living at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-h) nursing care~* General health status acceptable for participation in the study~* Fluency (oral and written) in English or Spanish~* If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose for at least 3 months. If receiving donepezil, any dose lower than 23 mg once daily.~* The patient is a non-smoker for at least 3 years.~* The patient or legal representative must agree to comply with the drawing of blood samples and with a lumbar puncture and the drawing of cerebrospinal fluid samples.~* The patient has a ratio of total tau/Aβ42 in cerebrospinal fluid \>= 0.28.~* Patient has a caregiver or legal representative responsible for administering the drug and recording the time.~Exclusion Criteria:~* Exposure to an experimental drug, experimental biologic or experimental medical device within the longer of 5 half-lives or 3 months before screening~* Enrollment in the previous PTI-125 trial~* A medical condition that would interfere with a lumbar puncture~* Residence in a skilled nursing facility and requiring 24 h care.~* Clinically significant laboratory test results~* Clinically significant untreated hypothyroidism~* Insufficiently controlled diabetes mellitus~* Renal insufficiency (serum creatinine \> ULN)~* Malignant tumor within 3 years before screening (except squamous and basal cell carcinoma or cervical carcinoma in situ or localized prostate cancer or localized stage 1 bladder cancer)~* History of ischemic colitis or ischemic enterocolitis~* Unstable medical condition that is clinically significant in the judgment of the investigator~* Alanine transaminase (ALT) or aspartate transaminase (AST) \> ULN or total bilirubin \> ULN.~* History of myocardial infarction or unstable angina within 6 months before screening~* History of more than 1 myocardial infarction within 5 years before screening~* Clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (patients with a pacemaker are acceptable)~* Symptomatic hypotension, or uncontrolled hypertension~* Clinically significant abnormality on screening electrocardiogram (ECG), including but not necessarily limited to a confirmed corrected QT interval value \>= 450 msec for males or \>= 470 msec for females.~* Stroke within 18 months before screening, or history of a stroke concomitant with onset of dementia~* History of brain tumor or other clinically significant space-occupying lesion on CT or MRI~* Head trauma with clinically significant loss of consciousness within 12 months before screening or concurrent with the onset of dementia~* Onset of dementia secondary to cardiac arrest, surgery with general anesthesia, or resuscitation~* Specific degenerative Central Nervous System disease diagnosis other than Alzheimer's disease (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome, Frontotemporal Dementia, Parkinson's disease)~* Wernicke's encephalopathy~* Active acute or chronic Central Nervous System infection~* Donepezil 23 mg quaque die currently or within 3 months prior to randomization~* Discontinued AChEI \< 30 days prior to randomization~* Antipsychotics; low doses are allowed only if the subject has received a stable dose for at least 3 months before randomization~* Tricyclic antidepressants and monoamine oxidase inhibitors~* Anxiolytics or sedative-hypnotics, including barbiturates (unless given in low doses for benign tremor); low doses of benzodiazepines and zolpidem are allowed~* Immunosuppressants, including systemic corticosteroids, if taken in clinically immunosuppressive doses (Steroid use for allergy or other inflammation is permitted.)~* Antiepileptic medications if taken for control of seizures~* Chronic intake of opioid-containing analgesics~* Sedating H1 antihistamines~* Nicotine therapy (all dosage forms including a patch), varenicline (Chantix), or similar therapeutic agent within 30 days before screening~* Clinically significant illness within 30 days of enrollment~* History of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease~* Positive serum hepatitis B surface antigen (HBsAg) or positive hepatitis C virus HCV antibody test at screening~* Positive HIV test at screening~* Positive urine drug test at screening~* Loss of a significant volume of blood (\> 450 mL) within 4 weeks prior to the study~* Suicidality on C-SSRS at screening

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Cohort (Type: PLACEBO_COMPARATOR): Subjects administered placebo oral tablets twice daily (BID)
- Simufilam (PTI-125) 100 mg tablets Cohort (Type: EXPERIMENTAL): Subjects administered simufilam (PTI-125) 100 mg oral tablets twice daily (BID)
- Simufilam (PTI-125) 50 mg tablets Cohort (Type: EXPERIMENTAL): Subjects administered simufilam (PTI-125) 50 mg oral tablets twice daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).